NASDAQ · Biotechnology

UroGen Pharma Ltd. (URGN) Stock

$37.06 +0.21% NASDAQ: URGN Healthcare

Valuation

MetricValue
Price$37.06
Market Cap$1.81B
P/E Ratio-20.56
P/B Ratio-15.49
P/S Ratio10.51
EPS (TTM)$-3.19
52-Week High$50.81
52-Week Low$15.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE81.78%
ROA-38.65%
ROCE-34.96%
Gross Margin89.85%
Operating Margin-77.02%
Net Margin-51.73%
Debt/Equity-1.48
Current Ratio4.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$48.0M$64.0M$83.0M$90.0M$110.0M
Operating Profit$-92.0M$-79.0M$-66.0M$-97.0M$-125.0M
Net Profit$-111.0M$-110.0M$-102.0M$-127.0M$-153.0M
EPS$-4.96$-4.79$-3.55$-2.96$-3.19
Op Margin-192.1%-122.8%-79.2%-107.1%-113.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$120.0M$136.0M$178.0M$286.0M$200.0M
Total Liabilities$111.0M$225.0M$244.0M$295.0M$306.0M
Cash$44.0M$55.0M$95.0M$172.0M$111.0M
Borrowings$0$99.0M$99.0M$123.0M$128.0M

Latest News

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks · Jul 30, 2026 UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 GlobeNewswire · Jul 29, 2026 Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? Stocktwits · Jul 22, 2026 Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 Barchart · Jul 17, 2026 Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating MT Newswires · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-85.0M$-88.0M$-76.0M$-97.0M$-162.0M
Investing Cash Flow$3.0M$1.0M$-1.0M$-21.0M$61.0M
Financing Cash Flow$72.0M$0$50.0M$19.0M$0
Net Cash Flow$-9.0M$11.0M$40.0M$77.0M$-61.0M
Free Cash Flow$-86.0M$-88.0M$-77.0M$-97.0M$-163.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.41
EV / EBITDA-29.70
FCF Yield-8.03%
Quick Ratio3.41
Interest Coverage-1.93
Return 1Y148.00%
Return 3Y352.74%
Return 5Y174.90%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CGONCG Oncology, Inc. $64.65 +2.19% -26.26 $5.70B 0.00%
RLMDRelmada Therapeutics, Inc. $3.17 -2.46% -3.91 $332.50M 0.00%

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is led by CEO Elizabeth A. Barrett, employs 234 people, headquartered in US, publicly traded since 2017.

UroGen Pharma Ltd. (URGN) stock trades at $37.06 with a market capitalization of $1.81B. The stock is valued at a price-to-earnings (P/E) ratio of -20.56, price-to-book of -15.49, price-to-sales of 10.51. Over the past 52 weeks the stock has ranged between $15.86 and $50.81, and currently trades 27.1% below its 52-week high.

On profitability, UroGen Pharma Ltd. generates a return on equity (ROE) of 81.78% — well above the market average, a sign of a high-quality business, return on capital employed of -34.96%, an operating margin of -77.02%, a net profit margin of -51.73%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1177.49 +0.67% JNJ Johnson & Johnson $260.66 +1.63% ABBV AbbVie Inc. $277.31 +1.80% MRK Merck & Company, Inc. Common Stock (new) $145.87 +2.45% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.88 +1.60% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $659.76 +1.19% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $150.98 +2.64% ABT Abbott Laboratories $99.45 +0.97% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides